NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Altimmune Inc (NASDAQ: ALT)

 
ALT Technical Analysis
3
As on 25th Apr 2025 ALT STOCK Price closed @ 5.07 and we RECOMMEND Sell for LONG-TERM with Stoploss of 7.57 & Sell for SHORT-TERM with Stoploss of 6.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ALTSTOCK Price

Open 5.12 Change Price %
High 5.21 1 Day -0.10 -1.93
Low 5.01 1 Week 0.54 11.92
Close 5.07 1 Month -0.13 -2.50
Volume 1023376 1 Year 2.37 87.78
52 Week High 13.81 | 52 Week Low 2.36
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
GNLN 0.01 -50.00%
AGMH 0.05 25.00%
OMEX 1.51 77.65%
NVDA 111.01 4.30%
WW 0.40 166.67%
TSLA 284.95 9.80%
INTC 20.05 -6.70%
OPEN 0.76 -2.56%
LMDX 0.02 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
ZWZZT 25.00 2375.25%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
WW 0.40 166.67%
WINVR 0.12 140.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
TFFP 0.06 -62.50%
ATMH 0.04 -60.00%
MILEW 0.06 -53.85%
LOTZW 0.01 -50.00%
 
 
ALT
Daily Charts
ALT
Intraday Charts
Whats New @
Bazaartrend
ALT
Free Analysis
 
ALT Important Levels Intraday
RESISTANCE5.46
RESISTANCE5.33
RESISTANCE5.26
RESISTANCE5.18
SUPPORT4.96
SUPPORT4.88
SUPPORT4.81
SUPPORT4.68
 
ALT Forecast April 2025
4th UP Forecast17.88
3rd UP Forecast13.77
2nd UP Forecast11.23
1st UP Forecast8.69
1st DOWN Forecast1.45
2nd DOWN Forecast-1.09
3rd DOWN Forecast-3.63
4th DOWN Forecast-7.74
 
ALT Weekly Forecast
4th UP Forecast6.13
3rd UP Forecast5.79
2nd UP Forecast5.58
1st UP Forecast5.37
1st DOWN Forecast4.77
2nd DOWN Forecast4.56
3rd DOWN Forecast4.35
4th DOWN Forecast4.01
 
ALT Forecast2025
4th UP Forecast29.22
3rd UP Forecast21.47
2nd UP Forecast16.69
1st UP Forecast11.9
1st DOWN Forecast-1.76
2nd DOWN Forecast-6.55
3rd DOWN Forecast-11.33
4th DOWN Forecast-19.08
 
 
ALT Other Details
Segment EQ
Market Capital 448676672.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ALT Address
ALT
 
ALT Latest News
 
Your Comments and Response on Altimmune Inc
 
ALT Business Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service